The latest personnel and boardroom moves by Michigan’s technology-focused companies and institutions
The latest personnel and boardroom announcements from Michigan’s technology-focused institutions and companies
Ann Arbor-based NanoBio Corp. Wednesday announced the initiation of two Phase 3 trials evaluating its drug candidate NB-001 as a topical treatment for cold sores, a step forward in its over-the-counter drug licensing agreement with GlaxoSmithKline Consumer Healthcare
NanoBio Corp. today announced a licensing agreement with the University of Michigan that provides NanoBio with rights to an antigen that has been shown to prevent urinary tract infections following intranasal vaccination
Ann Arbor-based NanoBio Corporation announced Tuesday that it has received a $6 million grant from the Bill & Melinda Gates Foundation to support development of an intranasal vaccine for Respiratory Syncytial Virus.
Ann Arbor-based NanoBio Corp. said Tuesday that it had been awarded its seventh United States patent covering its novel nanoemulsion technology. The new claims encompass methods of treating Herpes Simplex I infections, including herpes labialis, […]